Metastatic Human Epidermal Growth Factor 2 Positive Carcinoma Of Breast — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for metastatic human epidermal growth factor 2 positive carcinoma of breast. 14 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
14
Active US patents
63/100
Avg vulnerability
$463M
Annual revenue covered

Originators in Metastatic Human Epidermal Growth Factor 2 Positive Carcinoma Of Breast

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Seagen 14 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating metastatic human epidermal growth factor 2 positive carcinoma of breast. Each bar = one year. Y-axis scaled to peak year (6 patents).

2
27
2
31
2
32
2
33
6
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tukysa
tucatinib
 Seagen 14 63 $463M 2027-05-09

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9693989 Tukysa method of use 80 2027-05-09
9693989 Tukysa method of use 80 2027-05-09
11666572 Tukysa method of use 75 2038-04-27
11666572 Tukysa method of use 75 2038-04-27
12048698 Tukysa method of use 75 2038-04-27
12048698 Tukysa method of use 75 2038-04-27
11504370 Tukysa method of use 70 2033-03-25
11504370 Tukysa method of use 70 2033-03-25
11207324 Tukysa method of use 70 2038-04-27
11207324 Tukysa method of use 70 2038-04-27

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8648087 Tukysa composition of matter 10 2031-01-14
8648087 Tukysa composition of matter 10 2031-01-14
9457093 Tukysa method of use 62 2032-10-12
9457093 Tukysa method of use 62 2032-10-12
11207324 Tukysa method of use 70 2038-04-27
11207324 Tukysa method of use 70 2038-04-27
11504370 Tukysa method of use 70 2033-03-25
11504370 Tukysa method of use 70 2033-03-25
11666572 Tukysa method of use 75 2038-04-27
11666572 Tukysa method of use 75 2038-04-27

Related